Byung-Soo Kim1, Won-Ku Lee2, Kyoungjune Pak3, Junhee Han4, Gun-Wook Kim5, Hoon-Soo Kim5, Hyun-Chang Ko2, Moon-Bum Kim1, Seong-Jang Kim6. 1. Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Korea. 2. Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea; Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea; Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea. 3. Biomedical Research Institute, Pusan National University Hospital, Busan, Korea; Department of Nuclear Medicine, Pusan National University Hospital, Busan, Korea. 4. Department of Statistics, Hallym University, Chuncheon, Korea. 5. Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea. 6. Department of Nuclear Medicine, Pusan National University Hospital, Busan, Korea; Department of Nuclear Medicine, College of Medicine, Pusan National University, Busan, Korea; Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea. Electronic address: growthkim@daum.net.
Abstract
BACKGROUND: Evidence suggests that psoriasis might be associated with metabolic syndrome and an increased risk for cardiovascular disease. OBJECTIVE: To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT). METHODS: Patients with psoriasis and healthy controls underwent baseline 18F-FDG PET/CT imaging. Patients with moderate-to-severe psoriasis were treated with ustekinumab and underwent 18F-FDG PET/CT again after a Psoriasis Area and Severity Index of 75 was achieved. RESULTS: After a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and 5 parts of the aorta (P < .05). LIMITATIONS: Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population. CONCLUSION: Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.
BACKGROUND: Evidence suggests that psoriasis might be associated with metabolic syndrome and an increased risk for cardiovascular disease. OBJECTIVE: To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT). METHODS:Patients with psoriasis and healthy controls underwent baseline 18F-FDG PET/CT imaging. Patients with moderate-to-severe psoriasis were treated with ustekinumab and underwent 18F-FDG PET/CT again after a Psoriasis Area and Severity Index of 75 was achieved. RESULTS: After a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and 5 parts of the aorta (P < .05). LIMITATIONS: Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population. CONCLUSION:Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.
Authors: Benjamin Ungar; Ana B Pavel; Philip M Robson; Audrey Kaufman; Alison Pruzan; Patrick Brunner; Shivani Kaushik; James G Krueger; Mark G Lebwohl; Venkatesh Mani; Zahi A Fayad; Emma Guttman-Yassky Journal: J Allergy Clin Immunol Pract Date: 2020-07-25
Authors: Julie J Hong; Edward K Hadeler; Megan L Mosca; Nicholas D Brownstone; Tina Bhutani; Wilson J Liao Journal: J Psoriasis Psoriatic Arthritis Date: 2022-01-12
Authors: Di Yan; Andrew Blauvelt; Amit K Dey; Rachel S Golpanian; Samuel T Hwang; Nehal N Mehta; Bridget Myers; Zhen-Rui Shi; Gil Yosipovitch; Stacie Bell; Wilson Liao Journal: J Invest Dermatol Date: 2021-04-19 Impact factor: 7.590
Authors: Jochen H O Hoffmann; Christian Knoop; Knut Schäkel; Alexander H Enk; Eva N Hadaschik Journal: Acta Derm Venereol Date: 2021-05-25 Impact factor: 3.875